Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
July 20, 2018 at 12:53 PM EDT
The proceeds will be used to advance then company's experimental treatment for Fragile X Syndrome.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.